0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Kidney Disease Medication Market Research Report 2026
Published Date: 2026-02-09
|
Report Code: QYRE-Auto-28K18112
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Chronic Kidney Disease Medication Market Research Report 2024
BUY CHAPTERS

Global Chronic Kidney Disease Medication Market Research Report 2026

Code: QYRE-Auto-28K18112
Report
2026-02-09
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Chronic Kidney Disease Medication Market

The global Chronic Kidney Disease Medication market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Chronic Kidney Disease (CKD) Medication refers to a class of drugs specifically designed to manage and treat the progression of chronic kidney disease, a long-term condition characterized by the gradual loss of kidney function. These medications address various aspects of CKD, such as controlling blood pressure, managing blood sugar levels, correcting electrolyte imbalances, and treating complications like anemia and bone disease. The primary goal of CKD medications is to slow down kidney damage, alleviate symptoms, and improve the patient's quality of life.
The North American market for Chronic Kidney Disease Medication is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Chronic Kidney Disease Medication is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Chronic Kidney Disease Medication in Hospital is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Chronic Kidney Disease Medication include Amgen, Roche, FibroGen, AstraZeneca, GlaxoSmithKline, Akebia Therapeutics, Kissei, Teva Pharmaceutical Industries, Pfizer, Sanofi, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Chronic Kidney Disease Medication market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Kidney Disease Medication. The Chronic Kidney Disease Medication market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Chronic Kidney Disease Medication market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Chronic Kidney Disease Medication manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Chronic Kidney Disease Medication Market Report

Report Metric Details
Report Name Chronic Kidney Disease Medication Market
Segment by Type
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
  • Others
Segment by Application
  • Hospital
  • Specialist Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen, Roche, FibroGen, AstraZeneca, GlaxoSmithKline, Akebia Therapeutics, Kissei, Teva Pharmaceutical Industries, Pfizer, Sanofi, Novartis
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Chronic Kidney Disease Medication companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Kidney Disease Medication Market report?

Ans: The main players in the Chronic Kidney Disease Medication Market are Amgen, Roche, FibroGen, AstraZeneca, GlaxoSmithKline, Akebia Therapeutics, Kissei, Teva Pharmaceutical Industries, Pfizer, Sanofi, Novartis

What are the Application segmentation covered in the Chronic Kidney Disease Medication Market report?

Ans: The Applications covered in the Chronic Kidney Disease Medication Market report are Hospital, Specialist Clinic

What are the Type segmentation covered in the Chronic Kidney Disease Medication Market report?

Ans: The Types covered in the Chronic Kidney Disease Medication Market report are Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Kidney Disease Medication Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Angiotensin-Converting Enzyme (ACE) Inhibitors
1.2.3 Angiotensin II Receptor Blockers (ARBs)
1.2.4 Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chronic Kidney Disease Medication Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Kidney Disease Medication Market Perspective (2021–2032)
2.2 Global Chronic Kidney Disease Medication Growth Trends by Region
2.2.1 Global Chronic Kidney Disease Medication Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Chronic Kidney Disease Medication Historic Market Size by Region (2021–2026)
2.2.3 Chronic Kidney Disease Medication Forecasted Market Size by Region (2027–2032)
2.3 Chronic Kidney Disease Medication Market Dynamics
2.3.1 Chronic Kidney Disease Medication Industry Trends
2.3.2 Chronic Kidney Disease Medication Market Drivers
2.3.3 Chronic Kidney Disease Medication Market Challenges
2.3.4 Chronic Kidney Disease Medication Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Kidney Disease Medication Players by Revenue
3.1.1 Global Top Chronic Kidney Disease Medication Players by Revenue (2021–2026)
3.1.2 Global Chronic Kidney Disease Medication Revenue Market Share by Players (2021–2026)
3.2 Global Top Chronic Kidney Disease Medication Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Chronic Kidney Disease Medication Revenue
3.4 Global Chronic Kidney Disease Medication Market Concentration Ratio
3.4.1 Global Chronic Kidney Disease Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Kidney Disease Medication Revenue in 2025
3.5 Global Key Players of Chronic Kidney Disease Medication Head Offices and Areas Served
3.6 Global Key Players of Chronic Kidney Disease Medication, Products and Applications
3.7 Global Key Players of Chronic Kidney Disease Medication, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Chronic Kidney Disease Medication Breakdown Data by Type
4.1 Global Chronic Kidney Disease Medication Historic Market Size by Type (2021–2026)
4.2 Global Chronic Kidney Disease Medication Forecasted Market Size by Type (2027–2032)
5 Chronic Kidney Disease Medication Breakdown Data by Application
5.1 Global Chronic Kidney Disease Medication Historic Market Size by Application (2021–2026)
5.2 Global Chronic Kidney Disease Medication Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Chronic Kidney Disease Medication Market Size (2021–2032)
6.2 North America Chronic Kidney Disease Medication Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Chronic Kidney Disease Medication Market Size by Country (2021–2026)
6.4 North America Chronic Kidney Disease Medication Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Kidney Disease Medication Market Size (2021–2032)
7.2 Europe Chronic Kidney Disease Medication Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Chronic Kidney Disease Medication Market Size by Country (2021–2026)
7.4 Europe Chronic Kidney Disease Medication Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Chronic Kidney Disease Medication Market Size (2021–2032)
8.2 Asia-Pacific Chronic Kidney Disease Medication Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Chronic Kidney Disease Medication Market Size by Region (2021–2026)
8.4 Asia-Pacific Chronic Kidney Disease Medication Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Chronic Kidney Disease Medication Market Size (2021–2032)
9.2 Latin America Chronic Kidney Disease Medication Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Chronic Kidney Disease Medication Market Size by Country (2021–2026)
9.4 Latin America Chronic Kidney Disease Medication Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Kidney Disease Medication Market Size (2021–2032)
10.2 Middle East & Africa Chronic Kidney Disease Medication Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Chronic Kidney Disease Medication Market Size by Country (2021–2026)
10.4 Middle East & Africa Chronic Kidney Disease Medication Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Chronic Kidney Disease Medication Introduction
11.1.4 Amgen Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Chronic Kidney Disease Medication Introduction
11.2.4 Roche Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.2.5 Roche Recent Development
11.3 FibroGen
11.3.1 FibroGen Company Details
11.3.2 FibroGen Business Overview
11.3.3 FibroGen Chronic Kidney Disease Medication Introduction
11.3.4 FibroGen Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.3.5 FibroGen Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Chronic Kidney Disease Medication Introduction
11.4.4 AstraZeneca Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.4.5 AstraZeneca Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Chronic Kidney Disease Medication Introduction
11.5.4 GlaxoSmithKline Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.5.5 GlaxoSmithKline Recent Development
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Company Details
11.6.2 Akebia Therapeutics Business Overview
11.6.3 Akebia Therapeutics Chronic Kidney Disease Medication Introduction
11.6.4 Akebia Therapeutics Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.6.5 Akebia Therapeutics Recent Development
11.7 Kissei
11.7.1 Kissei Company Details
11.7.2 Kissei Business Overview
11.7.3 Kissei Chronic Kidney Disease Medication Introduction
11.7.4 Kissei Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.7.5 Kissei Recent Development
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Chronic Kidney Disease Medication Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.8.5 Teva Pharmaceutical Industries Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Chronic Kidney Disease Medication Introduction
11.9.4 Pfizer Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.9.5 Pfizer Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Chronic Kidney Disease Medication Introduction
11.10.4 Sanofi Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.10.5 Sanofi Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Chronic Kidney Disease Medication Introduction
11.11.4 Novartis Revenue in Chronic Kidney Disease Medication Business (2021–2026)
11.11.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Chronic Kidney Disease Medication Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Angiotensin-Converting Enzyme (ACE) Inhibitors
 Table 3. Key Players of Angiotensin II Receptor Blockers (ARBs)
 Table 4. Key Players of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
 Table 5. Key Players of Others
 Table 6. Global Chronic Kidney Disease Medication Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Chronic Kidney Disease Medication Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 8. Global Chronic Kidney Disease Medication Market Size by Region (US$ Million), 2021–2026
 Table 9. Global Chronic Kidney Disease Medication Market Share by Region (2021–2026)
 Table 10. Global Chronic Kidney Disease Medication Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 11. Global Chronic Kidney Disease Medication Market Share by Region (2027–2032)
 Table 12. Chronic Kidney Disease Medication Market Trends
 Table 13. Chronic Kidney Disease Medication Market Drivers
 Table 14. Chronic Kidney Disease Medication Market Challenges
 Table 15. Chronic Kidney Disease Medication Market Restraints
 Table 16. Global Chronic Kidney Disease Medication Revenue by Players (US$ Million), 2021–2026
 Table 17. Global Chronic Kidney Disease Medication Market Share by Players (2021–2026)
 Table 18. Global Top Chronic Kidney Disease Medication Players by Tier (Tier 1, Tier 2, and Tier 3), based on Chronic Kidney Disease Medication Revenue, 2025
 Table 19. Ranking of Global Top Chronic Kidney Disease Medication Companies by Revenue (US$ Million) in 2025
 Table 20. Global 5 Largest Players Market Share by Chronic Kidney Disease Medication Revenue (CR5 and HHI), 2021–2026
 Table 21. Global Key Players of Chronic Kidney Disease Medication, Headquarters and Area Served
 Table 22. Global Key Players of Chronic Kidney Disease Medication, Products and Applications
 Table 23. Global Key Players of Chronic Kidney Disease Medication, Date of General Availability (GA)
 Table 24. Mergers and Acquisitions, Expansion Plans
 Table 25. Global Chronic Kidney Disease Medication Market Size by Type (US$ Million), 2021–2026
 Table 26. Global Chronic Kidney Disease Medication Revenue Market Share by Type (2021–2026)
 Table 27. Global Chronic Kidney Disease Medication Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 28. Global Chronic Kidney Disease Medication Revenue Market Share by Type (2027–2032)
 Table 29. Global Chronic Kidney Disease Medication Market Size by Application (US$ Million), 2021–2026
 Table 30. Global Chronic Kidney Disease Medication Revenue Market Share by Application (2021–2026)
 Table 31. Global Chronic Kidney Disease Medication Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 32. Global Chronic Kidney Disease Medication Revenue Market Share by Application (2027–2032)
 Table 33. North America Chronic Kidney Disease Medication Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 34. North America Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2021–2026
 Table 35. North America Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2027–2032
 Table 36. Europe Chronic Kidney Disease Medication Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 37. Europe Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2021–2026
 Table 38. Europe Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2027–2032
 Table 39. Asia-Pacific Chronic Kidney Disease Medication Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 40. Asia-Pacific Chronic Kidney Disease Medication Market Size by Region (US$ Million), 2021–2026
 Table 41. Asia-Pacific Chronic Kidney Disease Medication Market Size by Region (US$ Million), 2027–2032
 Table 42. Latin America Chronic Kidney Disease Medication Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 43. Latin America Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2021–2026
 Table 44. Latin America Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2027–2032
 Table 45. Middle East & Africa Chronic Kidney Disease Medication Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 46. Middle East & Africa Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2021–2026
 Table 47. Middle East & Africa Chronic Kidney Disease Medication Market Size by Country (US$ Million), 2027–2032
 Table 48. Amgen Company Details
 Table 49. Amgen Business Overview
 Table 50. Amgen Chronic Kidney Disease Medication Product
 Table 51. Amgen Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 52. Amgen Recent Development
 Table 53. Roche Company Details
 Table 54. Roche Business Overview
 Table 55. Roche Chronic Kidney Disease Medication Product
 Table 56. Roche Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 57. Roche Recent Development
 Table 58. FibroGen Company Details
 Table 59. FibroGen Business Overview
 Table 60. FibroGen Chronic Kidney Disease Medication Product
 Table 61. FibroGen Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 62. FibroGen Recent Development
 Table 63. AstraZeneca Company Details
 Table 64. AstraZeneca Business Overview
 Table 65. AstraZeneca Chronic Kidney Disease Medication Product
 Table 66. AstraZeneca Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 67. AstraZeneca Recent Development
 Table 68. GlaxoSmithKline Company Details
 Table 69. GlaxoSmithKline Business Overview
 Table 70. GlaxoSmithKline Chronic Kidney Disease Medication Product
 Table 71. GlaxoSmithKline Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 72. GlaxoSmithKline Recent Development
 Table 73. Akebia Therapeutics Company Details
 Table 74. Akebia Therapeutics Business Overview
 Table 75. Akebia Therapeutics Chronic Kidney Disease Medication Product
 Table 76. Akebia Therapeutics Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 77. Akebia Therapeutics Recent Development
 Table 78. Kissei Company Details
 Table 79. Kissei Business Overview
 Table 80. Kissei Chronic Kidney Disease Medication Product
 Table 81. Kissei Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 82. Kissei Recent Development
 Table 83. Teva Pharmaceutical Industries Company Details
 Table 84. Teva Pharmaceutical Industries Business Overview
 Table 85. Teva Pharmaceutical Industries Chronic Kidney Disease Medication Product
 Table 86. Teva Pharmaceutical Industries Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 87. Teva Pharmaceutical Industries Recent Development
 Table 88. Pfizer Company Details
 Table 89. Pfizer Business Overview
 Table 90. Pfizer Chronic Kidney Disease Medication Product
 Table 91. Pfizer Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 92. Pfizer Recent Development
 Table 93. Sanofi Company Details
 Table 94. Sanofi Business Overview
 Table 95. Sanofi Chronic Kidney Disease Medication Product
 Table 96. Sanofi Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 97. Sanofi Recent Development
 Table 98. Novartis Company Details
 Table 99. Novartis Business Overview
 Table 100. Novartis Chronic Kidney Disease Medication Product
 Table 101. Novartis Revenue in Chronic Kidney Disease Medication Business (US$ Million), 2021–2026
 Table 102. Novartis Recent Development
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Chronic Kidney Disease Medication Picture
 Figure 2. Global Chronic Kidney Disease Medication Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Chronic Kidney Disease Medication Market Share by Type: 2025 vs 2032
 Figure 4. Angiotensin-Converting Enzyme (ACE) Inhibitors Features
 Figure 5. Angiotensin II Receptor Blockers (ARBs) Features
 Figure 6. Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Features
 Figure 7. Others Features
 Figure 8. Global Chronic Kidney Disease Medication Market Size by Application (US$ Million), 2021–2032
 Figure 9. Global Chronic Kidney Disease Medication Market Share by Application: 2025 vs 2032
 Figure 10. Hospital Case Studies
 Figure 11. Specialist Clinic Case Studies
 Figure 12. Chronic Kidney Disease Medication Report Years Considered
 Figure 13. Global Chronic Kidney Disease Medication Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 14. Global Chronic Kidney Disease Medication Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Chronic Kidney Disease Medication Market Share by Region: 2025 vs 2032
 Figure 16. Global Chronic Kidney Disease Medication Market Share by Players in 2025
 Figure 17. Global Chronic Kidney Disease Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Chronic Kidney Disease Medication Revenue in 2025
 Figure 19. North America Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. North America Chronic Kidney Disease Medication Market Share by Country (2021–2032)
 Figure 21. United States Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Canada Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Chronic Kidney Disease Medication Market Share by Country (2021–2032)
 Figure 25. Germany Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. France Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. U.K. Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Italy Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Russia Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Ireland Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Chronic Kidney Disease Medication Market Share by Region (2021–2032)
 Figure 33. China Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Japan Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. South Korea Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Southeast Asia Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. India Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Australia & New Zealand Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Chronic Kidney Disease Medication Market Share by Country (2021–2032)
 Figure 41. Mexico Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Brazil Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Chronic Kidney Disease Medication Market Share by Country (2021–2032)
 Figure 45. Israel Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Saudi Arabia Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. UAE Chronic Kidney Disease Medication Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Amgen Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 49. Roche Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 50. FibroGen Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 51. AstraZeneca Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 52. GlaxoSmithKline Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 53. Akebia Therapeutics Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 54. Kissei Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 55. Teva Pharmaceutical Industries Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 56. Pfizer Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 57. Sanofi Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 58. Novartis Revenue Growth Rate in Chronic Kidney Disease Medication Business (2021–2026)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture